Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Nucl Med Biol. 2022 May-Jun;108-109:16-23. doi: 10.1016/j.nucmedbio.2022.01.005. Epub 2022 Feb 4.
Positron Emission Tomography is an important molecular imaging technique for detection and diagnoses of various disease states. This work aims to develop novel titanium-45 (t = 3.08 h) PET tracers using Prostate Specific Membrane Antigen (PSMA) targeting vectors for imaging of prostate cancer as proof of concept for this relatively unexplored isotope.
Titanium-45 was produced on the University of Alabama at Birmingham (UAB) TR24 cyclotron using proton bombardments on natural scandium foils and separated using procedures described previously [1]. After purification, Titanium-45 was used to radiolabel two PSMA-targeting molecules; DFO-DUPA and LDFC-DUPA. Radiochemical yields were determined via radio-high purity liquid chromatography (radioHPLC). The radiolabeled compounds were tested both in vitro and in vivo using PSMA+ cell lines (LNCaP and 22Rv1) and PSMA- cell lines (PC3).
Titanium-45 was produced and purified in yields suitable for research studies. Radiochemical yields of up to 98 ± 1% were achieved with DFO-DUPA and 92 ± 7% with LDFC-DUPA. PSMA specific targeting was observed in vitro in PSMA positive cells (LNCaP (0.6% ± 0.05%) and confirmed by blocking (0.15% ± 0.04%) (P < 0.0001)), compared to uptake in the PSMA negative cells (PC3 (0.07% ± 0.008%)) and confirmed by blocking (0.07% ± 0.01%) (P = 0.5253). In vivo studies demonstrated statistically significant uptake in LNCaP tumors (2.3% ± 0.3% ID/g) compared to PC3 tumor uptake (0.1% ± 0.07%).
This work shows that titanium-45 can be used to radiolabel PSMA targeting compounds with high radiochemical yields. These radiolabeled compounds remain intact in serum for at least two half-lives of titanium-45, showing that these compounds would be appropriate for implementation in the clinical setting. This study shows the feasibility of using titanium-45 as positron emitting radiometal for use in imaging PSMA+ prostate cancer, and illustrates that further research is in this area is warranted.
正电子发射断层扫描是一种重要的分子影像学技术,可用于检测和诊断各种疾病状态。本研究旨在开发新型钛-45(t = 3.08 h)正电子发射断层扫描放射性示踪剂,使用前列腺特异性膜抗原(PSMA)靶向载体对前列腺癌进行成像,以此作为该相对未开发同位素的概念验证。
钛-45 是在阿拉巴马大学伯明翰分校(UAB)TR24 回旋加速器上通过质子轰击天然钪箔产生的,并使用以前描述的程序进行分离[1]。纯化后,使用钛-45 标记两种 PSMA 靶向分子;DFO-DUPA 和 LDFC-DUPA。通过放射性高效液相色谱法(radioHPLC)确定放射性化学产率。使用 PSMA+细胞系(LNCaP 和 22Rv1)和 PSMA-细胞系(PC3)在体外和体内测试了标记化合物。
成功生产和纯化了适合研究的钛-45。DFO-DUPA 的放射性化学产率高达 98 ± 1%,LDFC-DUPA 的放射性化学产率高达 92 ± 7%。在 PSMA 阳性细胞(LNCaP(0.6% ± 0.05%))中观察到 PSMA 特异性靶向,并用阻断剂(0.15% ± 0.04%)(P < 0.0001)证实,与 PSMA 阴性细胞(PC3(0.07% ± 0.008%))的摄取相比,用阻断剂(0.07% ± 0.01%)(P = 0.5253)证实。体内研究表明,LNCaP 肿瘤的摄取量有统计学意义(2.3% ± 0.3% ID/g),而 PC3 肿瘤的摄取量(0.1% ± 0.07%)。
本研究表明,钛-45 可用于高放射性化学产率标记 PSMA 靶向化合物。这些标记化合物在钛-45 的至少两个半衰期内仍保持完整,表明这些化合物适用于临床应用。本研究表明,使用钛-45 作为正电子发射放射性金属来成像 PSMA+前列腺癌是可行的,并说明该领域需要进一步研究。